Skip to content

Exelixis EXEL Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
$3.8M+88.1%
Incyte logo
IncyteINCY
$97.93M+2,923%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$57.3M+2,457%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$22.59M
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$23.6M-26.5%
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's stock issuance proceeds?
Exelixis (EXEL) reported stock issuance proceeds of $7.47M in Q1 2026.
How has Exelixis's stock issuance proceeds changed year-over-year?
Exelixis's stock issuance proceeds decreased by 35.7% year-over-year, from $11.63M to $7.47M.
What is the long-term trend for Exelixis's stock issuance proceeds?
Over 4 years (2021 to 2025), Exelixis's stock issuance proceeds has grown at a 19.2% compound annual growth rate (CAGR), from $24.31M to $49.14M.
What does stock issuance proceeds mean?
Cash received by the company from issuing new shares to employees or investors.
How do you interpret stock issuance proceeds?
Higher proceeds indicate significant employee participation in equity programs, which can be a positive sign of employee alignment but also results in shareholder dilution.
How does stock issuance proceeds compare across companies?
Standard line item for companies with robust equity incentive plans; peers often show consistent, modest inflows from these programs.